General practitioners’ use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study

Objective To understand general practitioners’ (GPs) use of individual risk factors (blood pressure and cholesterol levels) versus absolute risk in cardiovascular disease (CVD) risk management decision-making. Design Randomised experiment. Absolute risk, systolic blood pressure (SBP), cholesterol ratio (total cholesterol/high-density lipoprotein (TC/HDL)) and age were systematically varied in hypothetical cases. High absolute risk was defined as 5-year risk of a cardiovascular event >15%, high blood pressure levels varied between SBP 147 and 179 mm Hg and high cholesterol (TC/HDL ratio) between 6.5 and 7.2 mmol/L. Setting 4 GP conferences in Australia. Participants 144 Australian GPs. Outcomes GPs indicated whether they would prescribe cholesterol and/or blood pressure lowering medication. Analyses involved logistic regression. Results For patients with high blood pressure: 93% (95% CI 86% to 96%) of high absolute risk patients and 83% (95% CI 76% to 88%) of lower absolute risk patients were prescribed blood pressure medication. Conversely, 30% (95% CI 25% to 36%) of lower blood pressure patients were prescribed blood pressure medication if absolute risk was high and 4% (95% CI 3% to 5%) if lower. 69% of high cholesterol/high absolute risk patients were prescribed cholesterol medication (95% CI 61% to 77%) versus 34% of high cholesterol/lower absolute risk patients (95% CI 28% to 41%). 36% of patients with lower cholesterol (95% CI 30% to 43%) were prescribed cholesterol medication if absolute risk was high versus 10% if lower (95% CI 8% to 13%). Conclusions GPs’ decision-making was more consistent with the management of individual risk factors than an absolute risk approach, especially when prescribing blood pressure medication. The results suggest medical treatment of lower risk patients (5-year risk of CVD event <15%) with mildly elevated blood pressure or cholesterol levels is likely to occur even when an absolute risk assessment is specifically provided. The results indicate a need for improving uptake of absolute risk guidelines and GP understanding of the rationale for using absolute risk.

[1]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[2]  Jbs Board Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) , 2014, Heart.

[3]  N. Wong Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .

[4]  H. Krumholz Target cardiovascular risk rather than cholesterol concentration , 2013, BMJ.

[5]  Kirsten McCaffery,et al.  General practitioners’ use of different cardiovascular risk assessment strategies: a qualitative study , 2013, The Medical journal of Australia.

[6]  Ž. Reiner Polypill is not a ‘vaccine-like’ solution for primary cardiovascular disease prevention in all parts of the world , 2013, Journal of Epidemiology & Community Health.

[7]  T. Marshall,et al.  Patient Factors Influencing the Prescribing of Lipid Lowering Drugs for Primary Prevention of Cardiovascular Disease in UK General Practice: A National Retrospective Cohort Study , 2013, PloS one.

[8]  G. Elwyn,et al.  How can clinical practice guidelines be adapted to facilitate shared decision making? A qualitative key-informant study , 2013, BMJ quality & safety.

[9]  E. S. Ng,et al.  The efficiency of cardiovascular risk assessment: do the right patients get statin treatment? , 2013, Heart.

[10]  G. M. Allan,et al.  Agreement Among Cardiovascular Disease Risk Calculators , 2013, Circulation.

[11]  Ananda Sen,et al.  A national survey of the treatment of hyperlipidemia in primary prevention. , 2013, JAMA internal medicine.

[12]  D. Kerr,et al.  Building healthy bones throughout life: an evidence‐informed strategy to prevent osteoporosis in Australia , 2013 .

[13]  Shah Ebrahim,et al.  [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]. , 2013, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[14]  P. Gill,et al.  The Effect of Chance Variability in Blood Pressure Readings on the Decision Making of General Practitioners: An Internet-Based Case Vignette Study , 2012, PloS one.

[15]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[16]  John P A Ioannidis,et al.  Comparisons of established risk prediction models for cardiovascular disease: systematic review , 2012, BMJ : British Medical Journal.

[17]  T. Marshall,et al.  Patient and Other Factors Influencing the Prescribing of Cardiovascular Prevention Therapy in the General Practice Setting With and Without Nurse Assessment , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  J. Shaw,et al.  Guidelines for the management of absolute cardiovascular disease risk , 2012 .

[19]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[20]  Ž. Reiner,et al.  Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. , 2010, Atherosclerosis.

[21]  J. Jukema,et al.  Barriers to cardiovascular disease risk scoring and primary prevention in Europe. , 2010, QJM : monthly journal of the Association of Physicians.

[22]  A. Cass,et al.  Cardiovascular risk perception and evidence–practice gaps in Australian general practice (the AusHEART study) , 2010, The Medical journal of Australia.

[23]  Ersen B. Colkesen,et al.  Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check? , 2010, Archives of internal medicine.

[24]  N. Kerse,et al.  Perspectives of general practitioners towards evaluation and treatment of cardiovascular diseases among older people. , 2009, Journal of primary health care.

[25]  A. Cass,et al.  Gaps in cardiovascular disease risk management in Australian general practice , 2009, The Medical journal of Australia.

[26]  M. Neaverson How do the Australian guidelines for lipid‐lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999–2000 , 2009, The Medical journal of Australia.

[27]  P. Wilson,et al.  Physicians' attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions. , 2009, Current medical research and opinion.

[28]  J. Shaw,et al.  How do the Australian guidelines for lipid‐lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999–2000 , 2008, Medical Journal of Australia.

[29]  Stacey L Sheridan,et al.  Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature , 2008, BMC health services research.

[30]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[31]  Murray Stewart,et al.  Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[32]  M. Moser Historical Perspectives on the Management of Hypertension , 2006, Journal of clinical hypertension.

[33]  A. Tonkin,et al.  National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005. , 2005 .

[34]  M. Harris,et al.  GPs' views of absolute cardiovascular risk and its role in primary prevention. , 2005, Australian family physician.

[35]  Rod Jackson,et al.  Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk , 2005, The Lancet.

[36]  Trudy van der Weijden,et al.  Barriers to implementing cardiovascular risk tables in routine general practice , 2004, Scandinavian journal of primary health care.

[37]  N J Wald,et al.  A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.

[38]  J W Peabody,et al.  Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. , 2000, JAMA.

[39]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.